JP2023530785A5 - - Google Patents

Info

Publication number
JP2023530785A5
JP2023530785A5 JP2023519156A JP2023519156A JP2023530785A5 JP 2023530785 A5 JP2023530785 A5 JP 2023530785A5 JP 2023519156 A JP2023519156 A JP 2023519156A JP 2023519156 A JP2023519156 A JP 2023519156A JP 2023530785 A5 JP2023530785 A5 JP 2023530785A5
Authority
JP
Japan
Prior art keywords
crystal
xrpd pattern
peaks
irradiation
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530785A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/036082 external-priority patent/WO2021252309A1/en
Publication of JP2023530785A publication Critical patent/JP2023530785A/ja
Publication of JP2023530785A5 publication Critical patent/JP2023530785A5/ja
Priority to JP2026034319A priority Critical patent/JP2026108667A/ja
Pending legal-status Critical Current

Links

JP2023519156A 2020-06-08 2021-06-07 {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用 Pending JP2023530785A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026034319A JP2026108667A (ja) 2020-06-08 2026-03-04 {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035994P 2020-06-08 2020-06-08
US63/035,994 2020-06-08
PCT/US2021/036082 WO2021252309A1 (en) 2020-06-08 2021-06-07 Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026034319A Division JP2026108667A (ja) 2020-06-08 2026-03-04 {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用

Publications (2)

Publication Number Publication Date
JP2023530785A JP2023530785A (ja) 2023-07-19
JP2023530785A5 true JP2023530785A5 (cg-RX-API-DMAC7.html) 2024-06-13

Family

ID=78846441

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023519156A Pending JP2023530785A (ja) 2020-06-08 2021-06-07 {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用
JP2026034319A Pending JP2026108667A (ja) 2020-06-08 2026-03-04 {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026034319A Pending JP2026108667A (ja) 2020-06-08 2026-03-04 {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用

Country Status (8)

Country Link
EP (1) EP4161639A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023530785A (cg-RX-API-DMAC7.html)
KR (1) KR20230048501A (cg-RX-API-DMAC7.html)
CN (2) CN116056760A (cg-RX-API-DMAC7.html)
AU (1) AU2021289591A1 (cg-RX-API-DMAC7.html)
CA (1) CA3181665A1 (cg-RX-API-DMAC7.html)
MX (2) MX2022015524A (cg-RX-API-DMAC7.html)
WO (1) WO2021252309A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US12479808B2 (en) 2020-06-08 2025-11-25 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
PT2576524T (pt) * 2010-05-26 2017-11-17 Vtv Therapeutics Llc Resumo
IN2014DN09554A (cg-RX-API-DMAC7.html) * 2012-05-17 2015-07-17 Transtech Pharma Llc
CA2903433A1 (en) * 2013-03-04 2014-09-12 Vtv Therapeutics Llc Stable glucokinase activator compositions
HK1213197A1 (zh) * 2013-03-04 2016-06-30 Vtv治疗有限责任公司 包括葡糖激酶活化劑的固體組合物及其製備和使用方法
DK3556354T3 (da) * 2016-12-15 2025-08-04 Hua Medicine Shanghai Ltd Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf

Similar Documents

Publication Publication Date Title
JP2021119136A5 (cg-RX-API-DMAC7.html)
JPWO2022138988A5 (cg-RX-API-DMAC7.html)
JP2025176008A5 (cg-RX-API-DMAC7.html)
JP2023530786A5 (cg-RX-API-DMAC7.html)
JP2016528179A5 (cg-RX-API-DMAC7.html)
CN115461344B (zh) 一种glp-1受体激动剂的晶型a及其制备方法
RU2006126977A (ru) Кристаллическая форма соли 4-(3-хлор-4-(циклопропиламинокарбонил)аминофенокси)-7-метокси-6-хинолинкарбоксамида или сольвата этой соли и способы ее получения
WO2003037881A1 (en) α-FORM OR ß-FORM CRYSTAL OF ACETANILIDE DERIVATIVE
JP2009544696A (ja) バニロイド受容体アンタゴニストとしての、新規化合物、その異性体またはその薬学的に許容される塩;並びにそれを含む医薬組成物
JP2010524966A5 (cg-RX-API-DMAC7.html)
JP2013506670A5 (cg-RX-API-DMAC7.html)
JP2023083528A5 (cg-RX-API-DMAC7.html)
JP2025522923A (ja) Glp-1rアゴニストの塩並びにその製造方法及び応用
WO2010069124A1 (zh) 酰胺基噻唑衍生物及其制备方法和用途
JP4961357B2 (ja) イソオキサゾリン誘導体及びその製造方法
JP2025148397A5 (cg-RX-API-DMAC7.html)
JP2009534373A5 (cg-RX-API-DMAC7.html)
JP2011515421A5 (cg-RX-API-DMAC7.html)
JP2005529084A5 (cg-RX-API-DMAC7.html)
RU2004127585A (ru) Кристаллическая натриевая соль парекоксиба
IL319453A (en) Polymorph of a GLP-1R agonist compound, method of preparation thereof and use thereof
JP6473820B2 (ja) 塩酸ヨンケナフィルの多形体及びその調製方法、組成物並びに用途
JP2022540678A5 (cg-RX-API-DMAC7.html)
JP6275644B2 (ja) N−[2−({2−[(2S)−2−シアノピロリジン−1−イル]−2−オキソエチル}アミノ)−2−メチルプロピル]−2−メチルピラゾロ[1,5−a]ピリミジン−6−カルボキサミドの結晶
JP2024520897A5 (cg-RX-API-DMAC7.html)